MR spectroscopy in diagnosis and neurological decision-making

Seminars in Neurology

Volumn 28, Issue 4, 2008, Pages 407-422

  Xu, Victor ^a,b   Chan, Henry ^a   Lin, Alexander P ^a,b   Sailasuta, Napapon ^a,b   Valencerina, Samuel ^c   Tran, Thao ^a,b   Hovener, Jan ^a   Ross, Brian D ^a,b,d  

^a HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

^b Rudi Schulte Research Institute   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d NONE   (United States)

Author keywords

Choline; Creatine; Metabolite; MRI; N acetylaspartate; Spectroscopy

Indexed keywords

GLUTAMIC ACID;

ALZHEIMER DISEASE; BRAIN TUMOR; CLINICAL TRIAL; DECISION MAKING; FAMILIAL DISEASE; HUMAN; MEDICAL SPECIALIST; NEURAL STEM CELL; NEUROCHEMISTRY; NEUROIMAGING; NEUROPATHIC PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; STANDARDIZATION;

ASPARTIC ACID; CHOLINE; CREATINE; DECISION MAKING; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; NERVOUS SYSTEM DISEASES; NEUROCHEMISTRY;

EID: 56049109582     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0028-1083685     Document Type: Review

References (38)

1. Danielsen ER, Ross BD. Magnetic Resonance Spectroscopy in Diagnosis of Neurological Diseases. New York: Marcel Dekker; 2000
2. Gillard J, Waldman A, Barker P, eds. Clinical MR Neuroimaging. Cambridge, UK: Cambridge University Press; 2005
3. Ross B, Bluml S. Magnetic resonance spectroscopy of the human brain. Anat Rec 2001;265:54-84
4. Lin A, Nguy C-H, Shic F, et al. Accumulation of methylsulfonylmethane (MSM) in the human brain: identification by magnetic resonance spectroscopy. Toxicol Lett 2001;123:169-177
5. Hoevener J, Lin A, Tran T, et al. Neurospectroscopy will miss the boat - AGAIN: the need for universal standards and database. Proceedings of International Society for Magnetic Resonance in Medicine. Germany: May 2007
6. Harris K, Lin A, Bhattacharya P, et al. Regulation of NAA-synthesis in the human brain in vivo: Canavan's disease, Alzheimer's disease and schizophrenia. Adv Exp Med Biol 2006;576:263-273
7. Haseler LJ, Arcinue E, Danielsen ER, et al. Evidence from proton magnetic resonance spectroscopy for a metabolic cascade of neuronal damage in shaken baby syndrome. Pediatrics 1997;99:4-14
8. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 2000;13:129-153
9. Burtscher IM, Skagerberg G, Geijer B, et al. Proton MR spectroscopy and preoperative diagnostic accuracy: an evaluation of intracranial mass lesions characterized by stereotactic biopsy findings. AJNR Am J Neuroradiol 2000;21:84-93
10. Hollingworth W, Medina LS, Lenkinski RE, et al. A systematic literature review of magnetic resonance spectroscopy for the characterization of brain tumors. AJNR Am J Neuroradiol 2006;27:1404-1411
11. Chernov MF, Hayashi M, Izawa M, et al. Multivoxel proton MRS for differentiation of radiation-induced necrosis and tumor recurrence after gamma knife radiosurgery for brain metastases. Brain Tumor Pathol 2006;23:19-27
12. Schlemmer HP, Bachert P, Henze M, et al. Differentiation of radiation necrosis from tumor progression using proton magnetic resonance spectroscopy. Neuroradiology 2002;44:216-222
13. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494-500
14. Wang HC, Cheng SJ. The syndrome of acute bilateral basal ganglia lesions in diabetic uremic patients. J Neurol 2003;250:948-955
15. Lin AP, Tran TT, Ross BD. Impact of evidence-based medicine on magnetic resonance spectroscopy: clinical practice, reimbursement, and solutions. NMR Biomed 2006;19:476-483
16. Clinical Policy Bulletin: Magnetic Resonance Spectroscopy (MRS). April 13, 2007. Available at: http://www.aetna.com/cpb/medical/data/200_299/0202.html. Accessed January 2, 2008
17. De Stefano N, Filippi M, Miller D, et al. Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. Neurology 2007;69:1942-1952
18. Lin A, Shic F, Zapata M, et al. Magnetic resonance spectroscopy diagnosis of Alzheimer Disease: verification at autopsy. Neurobiol Aging 2002;23:S465
19. Lin A, Enriquez C, Ross BD. 1H magnetic resonance spectroscopy detection of chromosomal defects in Alzheimer's disease and Down syndrome. Proceedings from 11th International Society for Magnetic Resonance in Medicine; 2003
20. Godbolt AK, Waldman AD, MacManus DG, et al. MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology 2006;66:718-722
21. Adalsteinsson E, Sullivan EV, Kleinhans N, Spielman DM, Pfefferbaum A. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet 2000;355:1696-1697
22. Sailasuta N, Shriner K, Ross B. Evidence of decreased glutamate in the frontal lobe of HIV patients. Proceedings of the 15th Conference on Retroviruses and Opportunistic Infections, Boston, 2008. Poster E-168
23. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007;13:1102-1107
24. Weinberger DR. Schizophrenia drug says goodbye to dopamine. Nat Med 2007;13:1018-1019
25. Blüml S, Moreno-Torres A, Shic F, et al. Tricarboxylic acid cycle of glia in the in vivo human brain. NMR Biomed 2002;15:1-5
26. Harris KC, Bhattacharya P, Lin AP, et al. Apparent glutamate neurotransmitter rate is reduced in schizophrenic humans: a 1-13C glucose MRS study. Proceedings of the 21st Annual Scientific Meeting, ESMRMB 2004, Denmark. Abstract 62:S31
27. Siddall PJ, Stanwell P, Woodhouse A, et al. Magnetic resonance spectroscopy detects biochemical changes in the brain associated with chronic low back pain: a preliminary report. Anesth Analg 2006;102:1164-1168
28. Somorjai RL, Dolenko B, Nikulin AK, et al. Classification of 1H MR spectra of human brain neoplasms: the influence of preprocessing and computerized consensus diagnosis on classification accuracy. J Magn Reson Imaging 1996;6:437-444
29. Bluml S, Kopyov O, Jacques S, Ross BD. Activation of neurotransplants in humans. Exp Neurol 1999;158:121-125
30. Hoang TQ, Bluml S, Dubowitz DJ, et al. Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's Diseases. Neurology 1998;50:1033-1040
31. Ross BD. Long-term fetal cell transplant in Huntington disease: stayin' alive. Neurology 2008;70:815-816
32. Manganas LN, Zhang X, Li Y, et al. Magnetic resonance spectroscopy identifies neural progenitor cells in the live human brain. Science 2007;318:980-985
33. Stoica P, Sandgren N, Selen Y, et al. Frequency-domain method based on the singular value decomposition for frequency-selective NMR spectroscopy. J Magn Reson 2003;165:80-88
34. Mekle1 R, Gruetter R. Comparison of a TEM head coil with an 8 channel head array coil at 3 Tesla. Proceedings from 14th International Society for Magnetic Resonance in Medicine; 2006
35. Golman K, Ardenkjaer-Larsen JH, Petersson JS, et al. Molecular imaging with endogenous substances. Proc Natl Acad Sci U S A 2003;100:10435-10439
36. Bhattacharya P, Harris K, Lin A, et al. Ultrafast three dimensional free precession imaging. MAGMA 2005;18:245-256
37. Shic F, Lin A, Shelden CH, et al. Definition of the neurochemical patterns of human head injury in 1H MRS using wavelet analysis. Proceedings from 9th International Society for Magnetic Resonance in Medicine; 2001
38. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672-679